STOCK TITAN

Nuwellis Inc - NUWE STOCK NEWS

Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.

About Nuwellis Inc.

Nuwellis Inc. (Nasdaq: NUWE) is a specialized medical technology company dedicated to improving the lives of patients suffering from fluid overload, a condition commonly associated with heart failure, kidney dysfunction, and other critical illnesses. Headquartered in Minneapolis, with a wholly owned subsidiary in Ireland, Nuwellis focuses on the development and commercialization of innovative medical devices designed to address significant unmet clinical needs in fluid management.

Core Products and Solutions

The company’s flagship product, the Aquadex SmartFlow® system, is an advanced ultrafiltration therapy system that removes excess fluid from patients whose conditions are unresponsive to traditional medical management, including diuretics. This system is indicated for use in both adult and pediatric patients weighing 20 kilograms or more, offering a versatile solution for fluid overload management in both inpatient and outpatient settings. The Aquadex SmartFlow system is clinically validated to improve patient outcomes by reducing hospitalization rates, mitigating complications from fluid overload, and enhancing overall quality of life.

In addition to Aquadex, Nuwellis offers the RenalSense Clarity RMS, a kidney monitoring system that continuously measures and displays real-time urine output data, enabling healthcare providers to make timely and informed decisions in critical care scenarios. This complements the company’s broader mission of advancing patient care through cutting-edge medical technologies.

Market Significance and Industry Context

Nuwellis operates at the crossroads of medical technology, nephrology, and cardiology, addressing a critical gap in the management of fluid overload—a condition that affects millions of patients worldwide and contributes to significant healthcare costs. In the U.S. alone, fluid overload-related hospitalizations account for substantial expenditures due to prolonged stays and high readmission rates. By providing effective and scalable solutions, Nuwellis aims to reduce these burdens while improving patient outcomes.

The company’s technologies are particularly impactful in the treatment of acute decompensated heart failure (ADHF) and acute kidney injury (AKI), conditions where traditional therapies often fall short. Nuwellis has also made significant strides in pediatric care, offering life-saving solutions for critically ill children facing immune dysregulation and cytokine storms.

Business Model and Competitive Positioning

Nuwellis generates revenue primarily through the sale of its medical devices, alongside potential recurring income from consumables and service agreements. The company’s focus on clinical validation and collaboration with healthcare providers underscores its commitment to building trust and credibility within the medical community. By addressing both adult and pediatric markets, Nuwellis has carved out a unique niche, differentiating itself from competitors that may focus solely on broader or less specialized medical technologies.

In a competitive landscape that includes larger medical device companies and alternative fluid management solutions, Nuwellis stands out with its proprietary ultrafiltration system and emphasis on clinical efficacy. The company’s strategic partnerships with leading healthcare institutions further bolster its position as a trusted provider of advanced medical solutions.

Commitment to Innovation and Patient Care

At its core, Nuwellis is driven by a mission to transform patient care through science, collaboration, and innovation. The company’s relentless pursuit of addressing unmet clinical needs is evident in its continuous efforts to refine and expand its product offerings. By focusing on improving patient outcomes and reducing healthcare costs, Nuwellis plays a vital role in advancing the standard of care for fluid management and related conditions.

Rhea-AI Summary
Nuwellis, Inc. (NUWE) announces new real-world data demonstrating the effectiveness of Aquadex® ultrafiltration therapy with continuous hematocrit monitoring for pediatric patients with fluid overload. The data, featured in Pediatric Nephrology, show successful treatment of small patients without complications, validating Aquadex as an effective treatment option for fluid overload.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Nuwellis, Inc. (NUWE) Approves Equity Awards Under 2021 Inducement Plan for New Hires. The company's independent directors approved equity awards as material inducements to five individuals entering into employment with the company. The options to purchase a total of 1,943 shares of the company's common stock were granted at an exercise price of $0.60 per share, with a ten-year term and vesting over a period of four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
none
-
Rhea-AI Summary
Nuwellis, Inc. reported a 17% revenue growth for the third quarter of 2023, driven by a 26% increase in circuit sales. The company also achieved a 26% increase in therapy utilization and continued revenue growth across all customer categories. Despite a decrease in gross margin and a net loss of $3.4 million, Nuwellis closed a public offering with gross proceeds of $2.25 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
Rhea-AI Summary
Nuwellis, Inc. has appointed Dave McDonald and Dr. Archelle Georgiou, MD, to its board of directors. McDonald has extensive experience in finance and strategy, while Dr. Georgiou brings expertise in healthcare policy and patient education. The company aims to drive market penetration of its Aquadex® ultrafiltration therapy for patients with fluid overload.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.13%
Tags
management
-
Rhea-AI Summary
Nuwellis, Inc. announces that its strategic partner, SeaStar Medical Holding Corporation, has received an Approvable Letter from the FDA for its pediatric Selective Cytopheretic Device (SCD-PED). The SCD-PED will provide a new therapy option for children with acute kidney injury and sepsis. The Approvable Letter indicates that SeaStar Medical's HDE application meets the requirements for an Approval Order, with minor administrative steps remaining. Clinical data showed a 77% reduction in mortality rate and no dialysis dependency at Day 601,2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
-
Rhea-AI Summary
Nuwellis, Inc. to release Q3 2023 financial results on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
Rhea-AI Summary
Nuwellis, Inc. has closed its public offering of 150,000 units, consisting of Series J Convertible Redeemable Preferred Stock and warrants. The purchase price for one unit was $15. The Series J Convertible Preferred Stock has a term of three years and is convertible at the option of the holder. Dividends on the Series J Convertible Preferred Stock will be paid in-kind in additional shares. The gross proceeds from the offering were approximately $2.25 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
Nuwellis, Inc. announces pricing of public offering of 150,000 units
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.91%
Tags
-
Rhea-AI Summary
Nuwellis announces FDA approval progress for pediatric kidney therapy device
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.94%
Tags
none
Rhea-AI Summary
Nuwellis, Inc. to participate in fireside chat at Gilmartin Group Emerging Growth Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences acquisition

FAQ

What is the current stock price of Nuwellis (NUWE)?

The current stock price of Nuwellis (NUWE) is $1.2 as of March 3, 2025.

What is the market cap of Nuwellis (NUWE)?

The market cap of Nuwellis (NUWE) is approximately 5.4M.

What does Nuwellis Inc. specialize in?

Nuwellis Inc. specializes in medical technology solutions for fluid overload management, including its flagship Aquadex SmartFlow ultrafiltration system.

What is the Aquadex SmartFlow system?

The Aquadex SmartFlow system is an advanced ultrafiltration therapy device designed to remove excess fluid in patients unresponsive to traditional medical management.

Who are the primary users of Nuwellis' products?

Nuwellis' products are used by healthcare providers in inpatient and outpatient settings to treat adult and pediatric patients with fluid overload and related conditions.

How does Nuwellis differentiate itself from competitors?

Nuwellis differentiates itself through its proprietary ultrafiltration technology, focus on pediatric care, and commitment to clinically validated solutions.

What is the RenalSense Clarity RMS system?

The RenalSense Clarity RMS is a kidney monitoring system that provides real-time urine output data to support critical care decision-making.

What market challenges does Nuwellis address?

Nuwellis addresses challenges in managing fluid overload, a condition that contributes to high hospitalization rates and healthcare costs, by offering effective and scalable solutions.

In which medical fields does Nuwellis operate?

Nuwellis operates primarily in nephrology, cardiology, and critical care, focusing on fluid management and related conditions.

What is the significance of Nuwellis' focus on pediatric care?

Nuwellis' pediatric solutions address critical needs in managing immune dysregulation and fluid overload in children, providing life-saving therapies for vulnerable patients.
Nuwellis Inc

Nasdaq:NUWE

NUWE Rankings

NUWE Stock Data

5.38M
4.34M
1.6%
1.46%
17.27%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
EDEN PRAIRIE